Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Percheron Therapeutics ( (AU:PER) ) just unveiled an update.
Percheron Therapeutics faced a challenging period following the disappointing results of the avicursen phase IIb trial, leading to a decline in share price. Despite this setback, the company is evaluating the potential of its current drug candidates and actively seeking to diversify its portfolio with new opportunities. The board remains optimistic about announcing positive developments soon, aiming to rebuild shareholder value and make a meaningful impact on treating serious illnesses.
More about Percheron Therapeutics
Percheron Therapeutics operates in the pharmaceutical industry, focusing on the development of drugs for challenging diseases. The company is currently evaluating its drug candidates avicursen and atesidorsen, while also seeking to diversify its portfolio by identifying new promising drug candidates.
Average Trading Volume: 10,000
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.83M
See more insights into PER stock on TipRanks’ Stock Analysis page.
